Raymond James upgraded shares of Vitalhub (TSE:VHI - Free Report) to a moderate buy rating in a research note published on Wednesday morning,Zacks.com reports.
Several other analysts have also recently commented on VHI. Canaccord Genuity Group increased their price target on shares of Vitalhub from C$12.00 to C$12.50 and gave the company a "buy" rating in a research note on Thursday, January 16th. Scotiabank set a C$14.00 price objective on Vitalhub and gave the company an "outperform" rating in a research report on Thursday, January 30th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of C$12.08.
Read Our Latest Report on VHI
Vitalhub Trading Down 0.8 %
Shares of Vitalhub stock traded down C$0.08 during trading on Wednesday, reaching C$10.07. The company's stock had a trading volume of 55,217 shares, compared to its average volume of 145,427. The stock has a 50-day moving average price of C$10.46 and a two-hundred day moving average price of C$10.36. The stock has a market capitalization of C$544.71 million, a P/E ratio of 163.78, a price-to-earnings-growth ratio of 1.18 and a beta of 1.26. Vitalhub has a one year low of C$5.80 and a one year high of C$12.09.
About Vitalhub
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Further Reading
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
